Periodontitis - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 60 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Periodontitis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Periodontitis - Pipeline Review, H2 2016', provides an overview of the Periodontitis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Periodontitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Periodontitis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Periodontitis
- The report reviews pipeline therapeutics for Periodontitis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Periodontitis therapeutics and enlists all their major and minor projects
- The report assesses Periodontitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Periodontitis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Periodontitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Periodontitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table Of Content

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Periodontitis Overview 8
Therapeutics Development 9
Pipeline Products for Periodontitis - Overview 9
Pipeline Products for Periodontitis - Comparative Analysis 10
Periodontitis - Therapeutics under Development by Companies 11
Periodontitis - Therapeutics under Investigation by Universities/Institutes 12
Periodontitis - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Periodontitis - Products under Development by Companies 17
Periodontitis - Products under Investigation by Universities/Institutes 18
Periodontitis - Companies Involved in Therapeutics Development 19
Amyndas Pharmaceuticals LLC 19
C3 Jian, Inc 20
CSL Limited 21
Ensol Biosciences Inc. 22
Enzo Biochem, Inc. 23
Geistlich Pharma AG 24
Kaken Pharmaceutical Co., Ltd. 25
TGV-Laboratories 26
Periodontitis - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
AMY-101 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Drug to Antagonize C5aR for Periodontitis - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Enzo-D58 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
GM-0111 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Hesed-3000 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Mul-1867 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
PODCRC-OHS - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
R-10001 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Recombinant Protein to Activate Del-1 for Multiple Sclerosis and Periodontitis - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Small Molecule to Inhibit MMP and Cytokine for Immunology, Respiratory and Musculoskeletal Disorders - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Small Molecules for Periodontitis - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
ST-266 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Synthetic Peptides for Periodontitis - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
taurolidine - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
trafermin - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Periodontitis - Dormant Projects 53
Periodontitis - Discontinued Products 54
Periodontitis - Product Development Milestones 55
Featured News & Press Releases 55
Jun 15, 2016: Noveome Initiates Phase 2 Clinical Trial of ST266 to Treat Patients with Periodontitis 55
Mar 07, 2016: Penn Team Reverses Signs of Naturally Occurring Chronic Periodontitis 55
Oct 01, 2015: Kaken Submits a New Drug Application for KCB-1D�, Medicinal Product for Periodontal Regeneration 57
May 20, 2014: Penn Team Identifies Promising New Target for Gum Disease Treatment 57
Mar 30, 2012: Kaken Pharma To Initiate Additional Phase III Trial For KCB-1D 58
Oct 21, 2004: Kaken Pharmaceutical Announces Results Of Early Phase II Clinical Trial On KCB-1D 58
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 59
Disclaimer 60

List Of Tables

Number of Products under Development for Periodontitis, H2 2016 9
Number of Products under Development for Periodontitis - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Comparative Analysis by Unknown Stage Development, H2 2016 16
Products under Development by Companies, H2 2016 17
Products under Investigation by Universities/Institutes, H2 2016 18
Periodontitis - Pipeline by Amyndas Pharmaceuticals LLC, H2 2016 19
Periodontitis - Pipeline by C3 Jian, Inc, H2 2016 20
Periodontitis - Pipeline by CSL Limited, H2 2016 21
Periodontitis - Pipeline by Ensol Biosciences Inc., H2 2016 22
Periodontitis - Pipeline by Enzo Biochem, Inc., H2 2016 23
Periodontitis - Pipeline by Geistlich Pharma AG, H2 2016 24
Periodontitis - Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2016 25
Periodontitis - Pipeline by TGV-Laboratories, H2 2016 26
Assessment by Monotherapy Products, H2 2016 27
Number of Products by Stage and Target, H2 2016 29
Number of Products by Stage and Mechanism of Action, H2 2016 31
Number of Products by Stage and Route of Administration, H2 2016 33
Number of Products by Stage and Molecule Type, H2 2016 35
Periodontitis - Dormant Projects, H2 2016 53
Periodontitis - Discontinued Products, H2 2016 54